Abstract
Background: The Stanford group has reported excellent results with the Stanford V regimen for patients with bulky and/or advanced Hodgkin lymphoma (HL). However, Gobbi reported markedly inferior failure-free survival (FFS) comparing Stanford V to other regimens but included major deviations from the original program. We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data. Patients and methods: From June 1995 to May 2002, 126 patients with either locally extensive or advanced HL were treated with the 12-week Stanford V chemotherapy program followed by 36-Gy involved-field radiotherapy to sites initially ≥5 cm and/or to macroscopic splenic disease. Overall, 26% had stage IV disease and 20% had international prognostic score (IPS) ≥4. Overall survival (OS), disease-specific survival, progression-free survival (PFS), FFS, and freedom from second relapse (FF2R) were determined. Results: The 5- and 7-year OS were 90% and 88%, respectively. The 5-year FFS was 78%. IPS ≥4 was a significant independent predictor of worse OS and PFS. The FF2R was 64% at 3 years. Conclusion: Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL.
| Original language | English (US) |
|---|---|
| Article number | mdp337 |
| Pages (from-to) | 574-581 |
| Number of pages | 8 |
| Journal | Annals of Oncology |
| Volume | 21 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 16 2009 |
| Externally published | Yes |
Fingerprint
Keywords
- Combined modality
- Hodgkin lymphoma
- Involved-field radiotherapy
- Stanford V
ASJC Scopus subject areas
- Hematology
- Oncology
Cite this
Stanford V program for locally extensive and advanced Hodgkin lymphoma : The Memorial Sloan-Kettering Cancer Center experience. / Edwards-Bennett, S. M.; Jacks, L. M.; Moskowitz, Craig; Wu, E. J.; Zhang, Z.; Noy, A.; Portlock, C. S.; Straus, D. J.; Zelenetz, A. D.; Yahalom, J.
In: Annals of Oncology, Vol. 21, No. 3, mdp337, 16.09.2009, p. 574-581.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Stanford V program for locally extensive and advanced Hodgkin lymphoma
T2 - The Memorial Sloan-Kettering Cancer Center experience
AU - Edwards-Bennett, S. M.
AU - Jacks, L. M.
AU - Moskowitz, Craig
AU - Wu, E. J.
AU - Zhang, Z.
AU - Noy, A.
AU - Portlock, C. S.
AU - Straus, D. J.
AU - Zelenetz, A. D.
AU - Yahalom, J.
PY - 2009/9/16
Y1 - 2009/9/16
N2 - Background: The Stanford group has reported excellent results with the Stanford V regimen for patients with bulky and/or advanced Hodgkin lymphoma (HL). However, Gobbi reported markedly inferior failure-free survival (FFS) comparing Stanford V to other regimens but included major deviations from the original program. We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data. Patients and methods: From June 1995 to May 2002, 126 patients with either locally extensive or advanced HL were treated with the 12-week Stanford V chemotherapy program followed by 36-Gy involved-field radiotherapy to sites initially ≥5 cm and/or to macroscopic splenic disease. Overall, 26% had stage IV disease and 20% had international prognostic score (IPS) ≥4. Overall survival (OS), disease-specific survival, progression-free survival (PFS), FFS, and freedom from second relapse (FF2R) were determined. Results: The 5- and 7-year OS were 90% and 88%, respectively. The 5-year FFS was 78%. IPS ≥4 was a significant independent predictor of worse OS and PFS. The FF2R was 64% at 3 years. Conclusion: Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL.
AB - Background: The Stanford group has reported excellent results with the Stanford V regimen for patients with bulky and/or advanced Hodgkin lymphoma (HL). However, Gobbi reported markedly inferior failure-free survival (FFS) comparing Stanford V to other regimens but included major deviations from the original program. We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data. Patients and methods: From June 1995 to May 2002, 126 patients with either locally extensive or advanced HL were treated with the 12-week Stanford V chemotherapy program followed by 36-Gy involved-field radiotherapy to sites initially ≥5 cm and/or to macroscopic splenic disease. Overall, 26% had stage IV disease and 20% had international prognostic score (IPS) ≥4. Overall survival (OS), disease-specific survival, progression-free survival (PFS), FFS, and freedom from second relapse (FF2R) were determined. Results: The 5- and 7-year OS were 90% and 88%, respectively. The 5-year FFS was 78%. IPS ≥4 was a significant independent predictor of worse OS and PFS. The FF2R was 64% at 3 years. Conclusion: Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL.
KW - Combined modality
KW - Hodgkin lymphoma
KW - Involved-field radiotherapy
KW - Stanford V
UR - http://www.scopus.com/inward/record.url?scp=77949630205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949630205&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdp337
DO - 10.1093/annonc/mdp337
M3 - Article
VL - 21
SP - 574
EP - 581
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 3
M1 - mdp337
ER -